Block and tackle: CTLA4Ig takes on lupus

Anne Davidson, B. Diamond, D. Wofsy, D. Daikh

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Blockade of antigen nonspecific costimulatory signals is a promising approach for the treatment of autoimmune diseases including systemic lupus erythematosus (SLE). CTLA4Ig, an antagonist of the CD28/B7 costimulatory interaction, effectively prevents SLE onset in several murine models and, when used in combination with cyclophosphamide, can induce remission of active SLE nephritis. In this review we describe the known mechanisms of action of CTLA4Ig both in normal immunity and in autoimmune disease models and address issues about its activity that still need to be resolved. We discuss the preclinical use of CTLA4Ig in murine SLE models and the rationale for a clinical trial in SLE patients.

Original languageEnglish (US)
Pages (from-to)197-203
Number of pages7
Issue number3
StatePublished - 2005
Externally publishedYes


  • B cells
  • CTLA4Ig
  • Costimulation
  • Lymphocyte activation
  • SLE
  • T cells

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Block and tackle: CTLA4Ig takes on lupus'. Together they form a unique fingerprint.

Cite this